Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Reports link GLP-1 medications like Ozempic and Mounjaro to vision loss, prompting concerns over their safety.

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

There’s no direct link between vision loss and taking the weight loss and diabetes drugs such as Ozempic, Wegovy, Mounjaro, ...

Health experts are investigating a possible link between popular weight loss drugs like Ozempic and sudden blindness.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

"It's frankly scary what people will put up with when they're losing weight" Dr Michael Crotty on the rollout of Mounjaro ...

Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally due to the amount of weight people lose while ...

President Donald Trump lamented the cost of a diabetes medication that some Americans are taking for weight loss, or as the president referred to it, "the so-called fat drug." ...